Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population.

Conclusion: Our real-world study confirmed the noninferiority of cetuximab administered Q2W versus Q1W for OS.
PMID: 33118841 [PubMed - as supplied by publisher]

Source: Journal of Comparative Effectiveness Research - October 31, 2020 Category: General Medicine Tags: J Comp Eff Res Source Type: research